how do you use retatrutide 10 mg: vial guide for dosing, reconstitution, and protocols Retatrutide - GLP-1 / GIP

For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions

Managing blood sugar is essential as we age

The Phase 2 trial (Jastreboff et al., NEJM 2023) identified gastrointestinal effects as the most common adverse events

Pierre-Louis: Can you talk a bit about the role that compounding pharmacies have been playing with GLP-1s

The Phase 2 trial data showed consistent appetite suppression and continued weight maintenance through 48 weeks, with no evidence of the medication losing effectiveness over time